Autonomic dysregulation as a basis of cardiovascular, endocrine, and inflammatory disturbances associated with obstructive sleep apnea and other conditions of chronic hypoxia, hypercapnia, and acidosis

Medical Hypotheses

Volumn 62, Issue 6, 2004, Pages 852-856

  Yun, A Joon ^a,c   Lee, Patrick Y ^a   Bazar, Kimberly A ^b  

^a STANFORD UNIVERSITY   (United States)

^b San Mateo County Medical Center   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDOSIS; ATHEROSCLEROSIS; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ENDOCRINE DISEASE; HUMAN; HYPERCAPNIA; HYPERTENSION; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; MALADJUSTMENT; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER;

EID: 2542441728     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00322-0     Document Type: Article

References (69)

1. Kuna S, Remmers JE. Anatomy and physiology of upper airway obstruction. In: Kryger MH, Roth T, Dement WC, editors. Sleep medicine. Philadelphia, Pennsylvania: W.B. Saunders; 2000. p. 840-58.
2. Bassiri AG, Guilleminault C. Clinical features and evaluation of obstructive sleep apnea-hypopnea syndrome. In: Kryger MH, Roth T, Dement WC, editors. Sleep medicine. Philadelphia, Pennsylvania: W.B. Saunders; 2000. p. 869-78.
3. Strohl KP, Redline S. Recognition of obstructive sleep apnea. Am J Respir Crit Care Med 1996;154:279-89.
4. Smith PL, Schwartz AR. Biomechanics of the upper airway during sleep. In: Pack Al, editor. Sleep apnea: pathogenesis, diagnosis, and treatment. New York: Marcel Dekker, Inc.; 2002. p. 31-52.
5. Sakakibara H, Tong M, Matsushita K, Hirata M, Konishi Y, Suetsugu S. Cephalometric abnormalities in non-obese and obese patients with obstructive sleep apnoea. Eur Respir J 1999;13(2):403-10.
6. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003;41(9):1429-37.
7. Bananian S, Lehrman SG, Maguire GP. Cardiovascular consequences of sleep-related breathing disorders. Heart Dis 2002;4(5):296-305.
8. Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16(4):648-52.
9. Xu Y, Li S, Huang X, Cong B. Insulin-like growth factor-I and cognitive function in patients with obstructive sleep apnea syndrome. Zhonghua Yi Xue Za Zhi 2002;82(20): 1388-90.
10. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85(3):1151-8.
11. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86(2): 517-20.
12. Boethel CD. Sleep and the endocrine system: new associations to old diseases. Curr Opin Pulm Med 2002;8(6): 502-5.
13. Ozturk L, Unal M, Tamer L. The association of the severity of obstructive sleep apnea with plasma leptin levels. Arch Otolaryngol Head Neck Surg 2003;129(5):538-40.
14. Brooks B, Cistulli PA, et al. Obstructive sleep apnoea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab 1994;79:1681-5.
15. Shimizu K, Chin K, Nakamura T. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnea-hypopnea syndrome. Thorax 2002;57(5): 429-34.
16. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 2003;254(1):32-44.
17. Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;103: 1763-8.
18. Roche F, Court-Fortune I, Pichot V, Duverney D, Costes F, Emonot A, et al. Reduced cardiac sympathetic autonomic tone after long-term nasal continuous positive airway pressure in obstructive sleep apnoea syndrome. Clin Physiol 1999;19(2):127-34.
19. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897-904.
20. Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand 2003;177(3):385-90.
21. Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 2003;26(1):15-9.
22. Narkiewicz K, van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998;97(10):943-5.
23. Weihe E, Nohr D, Michel S, Muller S, Zentel HJ, Fink T, et al. Molecular anatomy of the neuro-immune connection. Int J Neurosci 1991;59:1-23.
24. Felten SY, Felten DL, Bellinger DL, Carlson SL, Ackerman KD, Madden KS, et al. Noradrenergic sympathetic innervation of lymphoid organs. Prog Allergy 1988;43:14-36.
25. Ernst PB, Song F, Klimpel GR, Haeberle H, Bamford KB, Crowe SE, et al. Regulation of the mucosal immune response. Am J Trop Med Hyg 1999;60:2-9.
26. Nagatomi R, Kaifu T, Okutsu M, Zhang X, Kanemi O, Ohmori H. Modulation of the immune system by the autonomic nervous system and its implication in immunological changes after training. Exerc Immunol Rev 2000;6:54-74.
27. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996;108:374-81.
28. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-9.
29. Suberville S, Bellocq A, Fouqueray B, Philippe C, Lantz O, Perez J, et al. Regulation of interleukin-10 production by beta-adrenergic agonists. Eur J Immunol 1996;26:2601-5.
30. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513-9.
31. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000;52(4):595-638.
32. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann NY Acad Sci 2002;966:290-303.
33. Hassig A, Kremer H, Liang WX, Stampfli K. The role of the Th-1 to Th-2 shift of the cytokine profiles of CD4 helper cells in the pathogenesis of autoimmune and hypercatabolic diseases. Med Hypotheses 1998;51(1):59-63.
34. Makino T, Noguchi Y, Yoshikawa T, Doi C, Nomura K. Circulating interleukin 6 concentrations and insulin resistance in patients with cancer. Br J Surg 1998;85(12):1658-62.
35. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 2003;4(6):487-92.
36. Frieri M. Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. Ann Allergy Asthma Immunol 2003;90(6 Suppl 3):34-40.
37. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study, 1987-1998. Circulation 2003;107(17):2190-5.
38. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003;92(1A):35i-42i.
39. Allen RP. Article reviewed: sleep apnoea and daytime sleepiness and fatigue: related to visceral obesity, insulin resistance, and hypercytokinemia. Sleep Med 2000;1:249-50.
40. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S50-5.
41. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002;87(7):3394-8.
42. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88(6):2404-11.
43. Young T, Finn L, Austin D, Peterson A. Menopausal status and sleep disordered breathing in the Wisconsin sleep cohort study. Am J Respir Crit Care Med 2003;167(9):1181-5.
44. Gianotti L, Pivetti S, Lanfranco F, et al. Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endocrinol Metab 2002;87(110):5052-7.
45. Nolte W, Radisch W, Rodenbeck A, et al. Polysomnographic findings in five adult patients with pituitary insufficiency before and after cessation of human growth hormone replacement therapy. Clin Endocrinol (Oxf) 2002;56(6):805-10.
46. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnoea syndrome in patients with polycystic ovarian syndrome. Sleep Med 2002;3:401-4.
47. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
48. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnoea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517-20.
49. Barbieri RL. Metformin for the treatment of polycystic ovary syndrome. Obstet Gynecol 2003;101(4):785-93.
50. Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C, Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001;76(5):1057-9.
51. Polotsky VY, Wilson JA, et al. The impact of insulin-dependent diabetes on ventilatory control in the mouse. Am J Respir Crit Care Med 2001;163:624-32.
52. Feinberg I. Untreated type 2 diabetes as a cause of daytime somnolence. Sleep 1993;16:82.
53. Vgontzas AN, Bixler EO, Tan T-L, Kantner D, Martin LF, Kales A. Obesity without sleep apnoea is associated with daytime sleepiness. Arch Intern Med 1998;158:1333-7.
54. Jaffe RB. Polycystic ovary syndrome is association with obstructive sleep apnoea and daytime sleepiness: role of insulin resistance. Obstet Gynecol Surv 2001;56:418-9.
55. Vgontzas AN, Chrousos GP. Sleep-disordered breathing, sleepiness, and insulin resistance: Is the latter a consequence, a pathogenetic factor, or both? Sleep Med 2002;3:389-91.
56. Nishihara K, Mori K, Endo S, Ohta T, Ohara K. Relationship between sleep efficiency and urinary excretion of catecholamines in bed-rested humans. Sleep 1985;8:110-7.
57. Linsell CR, Lightman SL, Mullen PE, Brown MJ, Causon RC. Circadian rhythms of epinephrine and norepinephrine in man. J Clin Endocrinol Metab 1985;60:1210-5.
58. Vaughn BV, Quint SR, Messenheimer JA, Robertson KR. Heart period variability in sleep. Electroen Clin Neurophysiol 1995;94:155-62.
59. Harrison GA. Stress, catecholamines, and sleep. Aviat Space Environ Med 1985;56:651-3.
60. Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol 2003;2(3): 167-76.
61. Mak RH. Insulin resistance but IGF-I sensitivity in chronic renal failure. Am J Physiol 1996;271(1 Pt 2):F114-9.
62. Kovacic V, Roguljic L, Kovacic V. Metabolic acidosis of chronically hemodialyzed patients. Am J Nephrol 2003;23(3):158-64.
63. Dzurik R, Spustova V, Janekova K. The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron 1995;69(3):281-5.
64. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119(7 Pt 2):655-60.
65. Sauerwein HP, Schols AM. Glucose metabolism in chronic lung disease. Clin Nutr 2002;21(5):367-71.
66. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002;121(5 Suppl):127S-30S.
67. Kemppainen J, Tsuchida H, Stolen K, Karlsson H, Bjornholm M, Heinonen OJ, et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003;550(1):305-15.
68. Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 2003;177(3):391-8.
69. Solin P, Kaye DM, Little PJ, Bergin P, Richardson M, Naughton MT. Impact of sleep apnea on sympathetic nervous system activity in heart failure. Chest 2003;123(4):1119-26.